Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-year safety and tolerability study of dupilumab in pediatric asthma
2017-003317-25Phase 3
- Sponsor
- Sanofi
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in asthma, sponsored by Sanofi. Primary endpoint: Treatment-emergent adverse events.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-003317-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003317-25.